|
medical sciences |
14 |
|
esophageal squamous cell carcinoma |
13 |
|
gastroenterology |
10 |
|
prognostic marker |
10 |
|
signal transduction |
10 |
|
tissue microarray |
10 |
|
tumor suppressor |
10 |
|
adult |
9 |
|
aged |
9 |
|
esophageal cancer |
9 |
|
neoadjuvant therapy |
9 |
|
aged, 80 and over |
8 |
|
epidemiology |
7 |
|
treatment outcome |
7 |
|
esophagectomy |
6 |
|
14-3-3σ |
5 |
|
alport's syndrome |
5 |
|
autopsy - methods |
5 |
|
biomarker |
5 |
|
blunt trauma |
5 |
|
chemoradiation response |
5 |
|
chemotherapy, adjuvant |
5 |
|
china |
5 |
|
cisplatin |
5 |
|
dyspepsia |
5 |
|
endoscopy |
5 |
|
esophageal cancer surgery |
5 |
|
esophageal carcinoma |
5 |
|
esophageal leiomyoma |
5 |
|
female |
5 |
|
fluorine-18-fluorodeoxyglucose |
5 |
|
gastroesophageal reflux |
5 |
|
hmgb1 |
5 |
|
humans |
5 |
|
liver laceration |
5 |
|
liver trauma |
5 |
|
middle aged |
5 |
|
minimally invasive autopsy |
5 |
|
mir-193b |
5 |
|
multiple injuries |
5 |
|
neoadjuvant chemoradiation |
5 |
|
non-operative management |
5 |
|
noncardiac chest pain |
5 |
|
penetrative trauma |
5 |
|
positron-emission tomography |
5 |
|
serum micrornas |
5 |
|
survival |
5 |
|
xpa |
5 |
|
acute inflammatory response |
4 |
|
antineoplastic agents |
4 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
|
bariatric surgery |
4 |
|
carcinoma, squamous cell - mortality - pathology - surgery - therapy |
4 |
|
carcinoma, squamous cell - mortality - pathology - therapy |
4 |
|
carcinoma, squamous cell - pathology - therapy |
4 |
|
cell survival |
4 |
|
cervical lymph node metastases |
4 |
|
chemotherapy |
4 |
|
cholecystectomy |
4 |
|
combined modality therapy |
4 |
|
cytokines |
4 |
|
cytology and histology |
4 |
|
esophageal neoplasms - mortality - pathology - surgery - therapy |
4 |
|
esophageal neoplasms - mortality - pathology - therapy |
4 |
|
esophageal neoplasms - pathology - therapy |
4 |
|
esophagectomy - methods |
4 |
|
gastrectomy |
4 |
|
gastric bypass |
4 |
|
hmga2 |
4 |
|
lymph node excision |
4 |
|
lymph nodes - pathology |
4 |
|
lymphatic metastasis |
4 |
|
male |
4 |
|
microarray |
4 |
|
natural orifice translumenal endoscopic surgery |
4 |
|
neck |
4 |
|
notes |
4 |
|
obesity |
4 |
|
oncology medical sciences |
4 |
|
palliative care - methods |
4 |
|
peg10 |
4 |
|
prognosis |
4 |
|
quality of life |
4 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
4 |
|
radiotherapy |
4 |
|
radiotherapy, adjuvant |
4 |
|
shank2 |
4 |
|
surgery |
4 |
|
thoracic neoplasms - pathology - therapy |
4 |
|
transvaginal surgery |
4 |
|
18f-fdg pet/ct |
3 |
|
barrett's esophagus |
3 |
|
bmi |
3 |
|
cd71 |
3 |
|
chemotherapeutic drug responses |
3 |
|
communicable diseases |
3 |
|
comparability |
3 |
|
diabetes remission |
3 |
|
esophagus |
3 |
|
foxo1 |
3 |
|
gastric dysplasia |
3 |
|
mir-1288 |
3 |
|
multimodality treatment |
3 |
|
natural orifice translumenal surgery (notes) |
3 |
|
natural orifice transluminal endoscopic surgery |
3 |
|
oesophageal |
3 |
|
oxygen carrier |
3 |
|
patient-reported outcomes |
3 |
|
percist |
3 |
|
peritoneoscopy |
3 |
|
physical activity |
3 |
|
population‐based study |
3 |
|
porcine model |
3 |
|
response evaluation |
3 |
|
sirna |
3 |
|
squamous cell carcinoma |
3 |
|
transanal endoscopic surgery |
3 |
|
transferrin receptor |
3 |
|
transrectal |
3 |
|
transvaginal cholecystectomy |
3 |
|
yq23 |
3 |
|
administration, oral |
2 |
|
anastomosis |
2 |
|
anastomosis, surgical - adverse effects |
2 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - therapeutic use |
2 |
|
asia-pacific |
2 |
|
asian barrett's consortium |
2 |
|
boerhaave’s |
2 |
|
breast carcinoma |
2 |
|
breast neoplasms - drug therapy - secondary |
2 |
|
bronchial fistula - etiology |
2 |
|
capecitabine |
2 |
|
carcinoma - pathology - surgery |
2 |
|
cyclophosphamide |
2 |
|
cyclophosphamide - administration & dosage |
2 |
|
deglutition disorders - etiology - therapy |
2 |
|
deoxycytidine - administration & dosage - analogs & derivatives |
2 |
|
diagnosis |
2 |
|
esophageal adenocarcinoma |
2 |
|
esophageal neoplasms - pathology - surgery |
2 |
|
esophageal neoplasms - surgery |
2 |
|
esophageal perforation |
2 |
|
esophagectomy - adverse effects |
2 |
|
esophagectomy for esophageal cancer |
2 |
|
esophagogastric junction - pathology - physiopathology |
2 |
|
esophagus - cancer - treatment. |
2 |
|
evaluation studies as topic |
2 |
|
fluorouracil - analogs & derivatives |
2 |
|
foregut surgery |
2 |
|
gastric outlet obstruction - etiology - therapy |
2 |
|
idarubicin |
2 |
|
idarubicin - administration & dosage |
2 |
|
ischemic gastric conduit |
2 |
|
laparoscopic colorectal resection |
2 |
|
lardiac stab injury |
2 |
|
metastatic breast cancer |
2 |
|
mie |
2 |
|
minimally invasive surgical approach |
2 |
|
modern results |
2 |
|
neoplasm recurrence, local - complications - mortality - physiopathology |
2 |
|
non-insulin-dependent diabetes - surgery |
2 |
|
oesophageal cancer |
2 |
|
oesophagectomy |
2 |
|
oral fluoropyrimidine |
2 |
|
outcome |
2 |
|
palliation |
2 |
|
palliative care |
2 |
|
pathogenesis |
2 |
|
perforation |
2 |
|
perforation score |
2 |
|
pericardiocentesis |
2 |
|
postoperative complications |
2 |
|
postoperative complications - surgery |
2 |
|
prague criteria |
2 |
|
recurrent esophageal carcinoma |
2 |
|
self-expanding metallic stent |
2 |
|
sepsis |
2 |
|
squamous cell cancer |
2 |
|
stents - adverse effects |
2 |
|
stomach neoplasms - pathology - surgery |
2 |
|
subxiphoid pericardial window |
2 |
|
surgical |
2 |
|
surgical reconstruction |
2 |
|
survey |
2 |
|
survival rate |
2 |
|
thoracotomy |
2 |
|
tobacco |
2 |
|
transoesophageal echocardiography |
2 |
|
treatment experience |
2 |
|
ventricular septal laceration |
2 |
|
asian country |
1 |
|
atrophic gastritis |
1 |
|
current situation |
1 |
|
endoscopic resection |
1 |
|
esophageal neoplasm |
1 |
|
esophagogastric junction |
1 |
|
esophagogastric junction adenocarcinoma |
1 |
|
helicobacter pylori |
1 |
|
obese |
1 |
|
predictive factors |
1 |
|
stomach neoplasm |
1 |
|
time trend |
1 |
|
type 2 diabetes |
1 |
